Total Payments
$97,297
2024 Payments
$1,165
Companies
28
Transactions
281
Medicare Patients
8,262
Medicare Billing
$813,490
Payment Breakdown by Category
Other$71,197 (73.2%)
Consulting$11,585 (11.9%)
Travel$8,393 (8.6%)
Food & Beverage$5,642 (5.8%)
Education$481.19 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $71,197 | 55 | 73.2% |
| Consulting Fee | $11,585 | 3 | 11.9% |
| Travel and Lodging | $8,393 | 33 | 8.6% |
| Food and Beverage | $5,642 | 166 | 5.8% |
| Education | $481.19 | 24 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| United Therapeutics Corporation | $79,883 | 137 | $0 (2024) |
| Merck Sharp & Dohme LLC | $7,136 | 15 | $0 (2024) |
| Gilead Sciences Inc | $6,843 | 11 | $0 (2017) |
| Inspire Medical Systems, Inc. | $454.28 | 5 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $430.84 | 15 | $0 (2024) |
| GlaxoSmithKline, LLC. | $392.94 | 25 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $374.94 | 21 | $0 (2024) |
| HARMONY BIOSCIENCES LLC | $245.35 | 6 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $231.55 | 5 | $0 (2024) |
| GENZYME CORPORATION | $229.80 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,165 | 37 | Inspire Medical Systems, Inc. ($302.45) |
| 2023 | $15,499 | 82 | Merck Sharp & Dohme LLC ($7,093) |
| 2022 | $9,130 | 32 | United Therapeutics Corporation ($8,759) |
| 2021 | $7,839 | 27 | United Therapeutics Corporation ($7,760) |
| 2020 | $4,971 | 6 | United Therapeutics Corporation ($4,959) |
| 2019 | $21,073 | 33 | United Therapeutics Corporation ($20,905) |
| 2018 | $20,075 | 28 | United Therapeutics Corporation ($19,932) |
| 2017 | $17,546 | 36 | United Therapeutics Corporation ($10,551) |
All Payment Transactions
281 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $74.04 | General |
| Category: NEUROLOGY | ||||||
| 12/10/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $29.61 | General |
| Category: NEUROLOGY | ||||||
| 12/06/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $68.59 | General |
| Category: NEUROLOGY | ||||||
| 12/05/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $130.21 | General |
| Category: NEUROLOGY | ||||||
| 10/07/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $34.34 | General |
| 10/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $43.32 | General |
| Category: RESPIRATORY | ||||||
| 08/03/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Education | Cash or cash equivalent | $99.99 | General |
| Category: Narcoplepsy | ||||||
| 06/05/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $30.48 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $23.78 | General |
| Category: RESPIRATORY | ||||||
| 06/03/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $37.32 | General |
| Category: IMMUNOLOGY | ||||||
| 05/29/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $19.22 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 05/28/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: RESPIRATORY | ||||||
| 05/22/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $25.97 | General |
| Category: Narcoplepsy | ||||||
| 05/21/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $15.68 | General |
| Category: IMMUNOLOGY | ||||||
| 05/17/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $32.74 | General |
| Category: Cardiology | ||||||
| 05/14/2024 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Food and Beverage | In-kind items and services | $19.98 | General |
| Category: Neurology | ||||||
| 05/08/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $33.46 | General |
| Category: Immunology | ||||||
| 05/07/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GLASSIA (Biological) | Food and Beverage | In-kind items and services | $22.22 | General |
| Category: IMMUNOLOGY | ||||||
| 04/30/2024 | Novartis Pharmaceuticals Corporation | XOLAIR (Drug) | Food and Beverage | In-kind items and services | $20.46 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 04/28/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $15.23 | General |
| Category: Respiratory | ||||||
| 03/29/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $13.20 | General |
| Category: Respiratory | ||||||
| 03/28/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GLASSIA (Biological) | Food and Beverage | In-kind items and services | $24.64 | General |
| Category: IMMUNOLOGY | ||||||
| 03/27/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $26.61 | General |
| Category: Immunology | ||||||
| 03/26/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $27.31 | General |
| Category: Narcoplepsy | ||||||
| 03/22/2024 | United Therapeutics Corporation | ORENITRAM (Drug), REMODULIN | Food and Beverage | In-kind items and services | $32.19 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 30 | 1,864 | 2,398 | $722,413 | $183,840 |
| 2022 | 32 | 2,081 | 2,646 | $427,366 | $201,948 |
| 2021 | 29 | 2,269 | 2,769 | $469,159 | $226,757 |
| 2020 | 28 | 2,048 | 2,585 | $458,095 | $200,945 |
Total Patients
8,262
Total Services
10,398
Medicare Billing
$813,490
Procedure Codes
127
All Medicare Procedures & Services
127 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 382 | 602 | $90,300 | $56,686 | 62.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 248 | 299 | $31,370 | $19,106 | 60.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 82 | 137 | $28,760 | $18,618 | 64.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 125 | 125 | $31,250 | $15,289 | 48.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 47 | 73 | $30,660 | $12,065 | 39.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 75 | 165 | $22,605 | $10,136 | 44.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 46 | 48 | $18,288 | $6,384 | 34.9% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 205 | 231 | $16,107 | $4,519 | 28.1% |
| 32555 | Aspiration of fluid from chest cavity using imaging guidance | Office | 2023 | 11 | 17 | $11,611 | $4,273 | 36.8% |
| 95810 | Sleep study in sleep lab (6 years or older) | Facility | 2023 | 47 | 47 | $10,857 | $4,166 | 38.4% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 143 | 161 | $12,880 | $4,153 | 32.2% |
| 95800 | Sleep study including heart rate, breathing, and sleep time | Office | 2023 | 32 | 32 | $14,720 | $3,716 | 25.2% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Facility | 2023 | 36 | 38 | $9,120 | $3,446 | 37.8% |
| 93451 | Insertion of tube in right heart chambers for measurement | Facility | 2023 | 29 | 31 | $333,498 | $3,094 | 0.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 24 | 24 | $6,216 | $2,444 | 39.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 17 | 25 | $4,875 | $2,237 | 45.9% |
| 31652 | Exam of lung airways and sampling of lymph nodes using an endoscope and ultrasound guidance, 1-2 lymph nodes | Facility | 2023 | 13 | 13 | $7,800 | $2,208 | 28.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $3,300 | $2,070 | 62.7% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 38 | 42 | $3,345 | $1,597 | 47.7% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Office | 2023 | 37 | 41 | $2,380 | $1,234 | 51.9% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 34 | 43 | $6,192 | $1,140 | 18.4% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2023 | 20 | 20 | $12,084 | $939.51 | 7.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 12 | 12 | $1,740 | $930.81 | 53.5% |
| 76604 | Ultrasound scan of chest | Office | 2023 | 13 | 17 | $2,040 | $765.17 | 37.5% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 19 | 19 | $3,838 | $578.74 | 15.1% |
About Dr. John Plankeel, M.D
Dr. John Plankeel, M.D is a Pulmonary Disease healthcare provider based in Lynchburg, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1538197744.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Plankeel, M.D has received a total of $97,297 in payments from pharmaceutical and medical device companies, with $1,165 received in 2024. These payments were reported across 281 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($71,197).
As a Medicare-enrolled provider, Plankeel has provided services to 8,262 Medicare beneficiaries, totaling 10,398 services with total Medicare billing of $813,490. Data is available for 4 years (2020–2023), covering 127 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Lynchburg, VA
- Active Since 06/28/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1538197744
Products in Payments
- ORENITRAM (Drug) $33,277
- NONE (Drug) $19,921
- TYVASO (Drug) $5,405
- Letairis (Drug) $4,992
- INSPIRE (Device) $454.28
- DUPIXENT (Biological) $325.72
- UPTRAVI (Drug) $291.56
- WAKIX (Drug) $245.35
- TRELEGY ELLIPTA (Drug) $224.27
- remede System (Device) $141.67
- TEZSPIRE (Biological) $125.40
- NUCALA (Biological) $118.43
- ELIQUIS (Drug) $110.87
- GLASSIA (Biological) $108.63
- TAVNEOS (Drug) $102.12
- MITRACLIP (Device) $97.94
- FASENRA (Biological) $91.32
- OPSUMIT (Drug) $90.87
- BREZTRI (Drug) $81.38
- OFEV (Drug) $78.42
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Lynchburg
Michael Milam, M.d, M.D
Pulmonary Disease — Payments: $7,325
Pulmonary Disease $7,325
Dr. Prema Madhuri Pamireddy, M.d, M.D
Pulmonary Disease — Payments: $3,049
Pulmonary Disease $3,049
Albert Baker, M.d, M.D
Pulmonary Disease — Payments: $2,273
Pulmonary Disease $2,273
Joseph Khoury, M.d, M.D
Pulmonary Disease — Payments: $316.96
Pulmonary Disease $316.96
Lisa Geier, N.p, N.P
Pulmonary Disease — Payments: $44.25
Pulmonary Disease $44.25
Carol Driskill, N.p, N.P
Pulmonary Disease
Pulmonary Disease